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Abstract
Background: In 2012, the World Health Organization recommended that needle and syringe programs offer their
clients low dead space insulin syringes with permanently attached needles. However, in many countries, these
syringes are not acceptable to a majority of people who inject drugs. This study assessed the feasibility of working
with needle and syringe programs to implement the WHO recommendation using low dead space detachable
needles. The study also assessed the acceptability of the needles.
Methods: Two needle and syringe programs in Tajikistan—one in Kulob and one in Khudjand—received 25,000
low dead space detachable needles each. The programs distributed low dead space detachable needles and a
marketing flyer that emphasized the relative advantages of the needles. Each program also enrolled 100 participants,
and each participant completed a baseline interview and a 2-month follow-up interview.
Results: At follow-up, 100% of participants reported trying the low dead space detachable needles, and 96% reported
that they liked using the needles. Both needle and syringe programs distributed all their needles within the
first 60 days of the project indicating use of the needles, even among clients who did not participate in the
study.
Conclusions: This project demonstrates that it is feasible for needle and syringe programs to offer and promote low
dead space needles to their clients. The findings indicate that low dead space needles are acceptable to needle and
syringe program clients in these Tajikistan cities. To reduce HIV and hepatitis C virus transmission, needle and syringe
programs should offer low dead space needles, low dead space insulin syringes in addition to standard needles, and
syringes to their clients.
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Background
Needle and syringe programs (NSPs) reduce the spread
of HIV and hepatitis C virus (HCV) among people who
inject drugs (PWID). However, inadequate funding [1]
and paraphernalia laws that criminalize needle and syr-
inge possession [2] diminish the effectiveness of NSPs in
many settings. Because the Global Fund to Fight AIDS,
Tuberculosis and Malaria [3] is shifting funding from
middle-income countries where many PWID live, efforts
to increase funding for NSPs in the near future face
serious challenges [4]. Additionally, despite attempts to
change paraphernalia laws, they remain widespread [5].
Efforts to sustain and increase funding for NSPs and to
advocate for the repeal of paraphernalia laws must be
redoubled. However, success in these endeavors will take
time. Meanwhile, PWID continue to share needles and
syringes, and HIV and HCV continue to spread. Conse-
quently, stopgap measures to slow HIV and HCV trans-
mission remain important in the interim.
Low dead space (LDS) needles and syringes represent
one such measure. The World Health Organization
(WHO) reviewed evidence on the differential risks of
HIV and HCV transmission associated with sharing
1-mL LDS insulin syringes with permanently attached
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needles compared with sharing high dead space (HDS)
needles and syringes [6–9]. Following the review, the
WHO concluded that the risks of HIV and HCV trans-
mission associated with sharing LDS insulin syringes are
lower than the risks associated with sharing HDS nee-
dles and syringes. In 2012, on the basis of this conclu-
sion, the WHO recommended that NSPs offer their
clients LDS insulin syringes [10, 11].
As part of the review process, the WHO commis-
sioned a qualitative study to assess PWID’s prefer-
ences regarding LDS syringes. Participants in the
qualitative study reported that it was important for
syringes to come in different volumes and to have de-
tachable needles [12]. To date, implementation of the
WHO recommendation remains limited in regions
where PWID use syringes with barrel capacities
greater than 1 mL and where PWID strongly prefer
detachable needles.
A major harm reduction supplier, Exchange Supplies
(www.exchangesupplies.org), developed LDS detachable
needles that fit on standard HDS syringes of different
volumes, thereby addressing the need for larger syringe
barrels and preferences for detachable needles. These
needles have the potential to significantly reduce the vol-
ume of dead space in a needle and syringe combination
compared with standard detachable needles [13]. Figure 1
illustrates the dead space in an HDS needle attached to
an HDS syringe (1.a), an LDS needle attached to an
HDS syringe (1.b), and an LDS insulin syringe with a
permanently attached needle (1.c). A recent laboratory
study compared the relative effects of LDS insulin syrin-
ges, LDS detachable needles attached to HDS syringes,
and HDS needle and syringe combinations on the recov-
ery of HCV. The researchers recovered HCV from 98%
of HDS needle and syringe combinations, 65% of LDS
detachable needles attached to HDS syringes, and 47%
of LDS insulin syringes immediately after use [14]; a
study that compared the relative effects of LDS detach-
able needles and LDS insulin syringes on HIV survival
reached similar conclusions [15].
Fig. 1 Illustrations of dead space in different needle and syringe combinations
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Before implementing the WHO recommendation,
NSPs must determine the lowest dead space option (i.e.,
LDS insulin syringes or LDS detachable needles) that is
acceptable to their clients. A previously published report
concluded that LDS insulin syringes were not compat-
ible with the needs and preferences of NSP clients in
Tajikistan [16]. The primary objectives of this study were
to assess the feasibility of NSPs distributing LDS detach-
able needles and the acceptability of these needles to
their clients. The study also sought to understand any
barriers to using the needles and attributes of the nee-
dles that could affect uptake. Because NSPs in Tajikistan
are very busy and have limited resources, distribution of
the needles could not require extensive training or place
an additional burden of NSP staff. Therefore, the re-
search team developed a one-page flyer that described





The Republic of Tajikistan, population 8 million, shares
a 1344-km border with Afghanistan. Poor socioeco-
nomic conditions and its location on the main heroin
trafficking route from Afghanistan contribute to cheap
heroin, injection drug use, and HIV in Tajikistan [17].
PWID account for about half of all HIV infections in
Tajikistan [17]. In 2015, 51 harm reduction sites
throughout the country provided HIV prevention ser-
vices to 13,456 PWID [18].
This project was conducted in two Tajikistan cities,
Kulob and Khudjand. Kulob, with an estimated popula-
tion of 100,000, is 120 miles southeast of the capital,
Dushanbe. Khudjand, located 190 miles north of
Dushanbe by car, has an estimated population of
170,000. Both cities are located on the Afghan opiate
drug trafficking routes and have experienced significant
increases in opiate consumption and in HIV and HCV
infections among PWID over the past two decades [17].
The NSP in Kulob distributes approximately 52,500 nee-
dles/syringes to 750 PWID per month, whereas the NSP
in Khudjand distributes 25,000 needles/syringes to 400
PWID per month.
Prior to the implementation of this study, the two
NSPs distributed HDS detachable needles and syringes,
but neither NSP distributes LDS detachable needles.
Most of the syringes that they distributed were 2 mL,
but they also distributed small numbers of 1-mL and
5-mL syringes. The HDS detachable needles ranged in
length from 1 to 1.5 in. and ranged from 25 to 21 gauge
in diameter. Both NSPs also distributed a small number
of the 1-mL LDS insulin syringes with permanently
attached needles. Both NSP continued to distribute this
entire range of needles throughout the study period.
Study design
The pilot test used a pre-post-test design to assess the
acceptability of LDS detachable needles among NSP
clients, the feasibility of NSPs implementing a low-
intensity intervention (i.e., distributing a flyer) to pro-
mote LDS detachable needles, and uptake of the needles
by their clients.
Study sample eligibility and recruitment procedures
Eligibility criteria for participation in an interview in-
cluded a minimum age of 18 years, self-report injecting
at least once a week, self-report obtaining syringes from
the NSP at least twice in the past 30 days, and report
planning to remain in the city for the next 3 months.
Both NSPs operated out of fixed sites and employed out-
reach workers who distributed syringes in the commu-
nity. Outreach workers informed their clients and other
people who injected drugs that they encountered in the
community about the study. Staff at each fixed-NSP site
informed clients who visited the NSP about the study. A
trained NSP staff member at each site screened each po-
tential participant after he or she expressed interest in
the study. The NSP staff member described the study in
greater detail to potential participants who met the eligi-
bility criteria. Staff obtained informed consent from
those who met the eligibility criteria and interested in
participating. After obtaining informed consent, the NSP
staff member collected locator information from the par-
ticipant prior to the beginning of the interview.
Assessment procedures
Trained NSP personnel administered face-to-face inter-
views at study intake and at 2-month follow-up. Mem-
bers of the research team, who were fluent in English,
Tajik, and Russian, translated the questionnaire into
Tajik and Russian prior to programming the question-
naires as computer-assisted personal interviews (CAPI).
The following questions provide examples of question-
naire items that were used in the analyses:
1. How many times did you inject drugs in the last
30 days?
2. How many times in the last 30 days have you
injected drugs with a needle that was not a low-
waste needle?
3. How many times did you inject heroin mixed with
dimedrol in the last 30 days?
4. Why did you use a needle that was not a low-waste
needle? (responses are mutually exclusive)
(a) I prefer these needles.
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(b) I could not get/I did not have a low-waste
needle.
(c) The low-waste needles are the wrong size.
(d) The low-waste needles are of poor quality.
(e) Other reason.
All study participants underwent rapid HIV testing
at study intake. HIV testing was performed at the Na-
tional AIDS Center located in each city. Additionally,
dried blood spot specimens for HIV viral load testing
were collected from the participants who tested posi-
tive for HIV.
Intervention
Social cognitive theory and diffusion of innovations the-
ory [18, 19] provided the theoretical basis for the interven-
tion. According to the social cognitive theory, learning
must be accompanied by facilitation (i.e., removal of bar-
riers) before information can be acted on [20]. For this
research, the study donated LDS detachable needles to
the participating NSP in each city. Subsequently, NSP
outreach workers distributed flyers that described the
advantages of LDS detachable needles to their clients
and began offering their clients LDS detachable needles.
The flyer referred to the needles as “low-waste” and
emphasized the following relative advantages of LDS de-
tachable needles (Fig. 2): (1) LDS detachable needles re-
duce the amount of drug that is retained and wasted in
the dead space; (2) LDS detachable needles facilitate ac-
curate division of liquefied drug solution between two
PWID; and (3) LDS detachable needles reduce the vol-
ume of blood retained in a needle and syringe after use,
which may decrease the risk of HIV and HCV transmis-
sion if they are shared. Previous research suggested that
these advantages would be compatible with the values
and beliefs of PWID in Tajikistan [16].
The research team explained the purpose study to the
outreach workers and answered any questions that they
Fig. 2 Image of marketing flyer to promote LDS detachable needles
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had regarding the flyers and the LDS detachable needles.
Outreach workers did not receive any additional training
on what to tell people when they distributed the flyers.
Each participant received 20 LDS detachable needles
at enrolment. Participants could obtain additional LDS
detachable needles from the NSP fixed site or outreach
workers until all the needles were distributed.
Measures
Feasibility
The primary feasibility measures included NSP distribu-
tion of LDS detachable needles and NSP distribution of
flyers.
Penetration
In addition to the 100 NSP clients in each city who par-
ticipated in the study, each NSP offered the LDS detach-
able needles to all their clients. The time required for an
NSP to distribute all 25,000 needles received provides an
indirect measure of penetration of the intervention (i.e.,
LDS detachable needles) into the population of NSP
clients.
Acceptability
The follow-up questionnaire included two questions to
assess the acceptability of the LDS detachable needles.
The first question asked if a participant had used LDS
detachable needles; the second asked if the participant
liked using them.
Attributes
To assess the attributes of LDS detachable needles that
may affect adoption, participants who responded that
they liked using LDS detachable needles were asked add-
itional questions regarding relative advantages, such as
reduced wasted drug, increased accuracy of dividing li-
quefied drug solution, and less retention of blood after
use. Participants were also asked if they observed other
PWID injecting with an LDS needle and if they told
other PWID about using LDS detachable needles.
Uptake
Measures of uptake included (1) any use of LDS detach-
able needles in the past 30 days, (2) no use of LDS de-
tachable needles in the past 30 days, and (3) and
number of injections with an HDS needle in the past
30 days. To assess the factors that affected the uptake,
participants who reported using any HDS needles in the
past 30 days were asked why they used the HDS needles.
Sustainability
The United Nations Development Programme (UNDP),
the principal recipient of the Global Fund grants in
Tajikistan, procures needles and syringes and distributes
them to NSPs across the country. This arrangement pre-
vented the participating NSPs from purchasing LDS de-
tachable needles on their own. Therefore, this pilot
study did not assess sustainability.
HIV antibody testing and HIV viral load testing
All HIV antibody testings in Tajikistan are performed at
AIDS Centers that are run by the government of
Tajikistan. Following completion of the baseline inter-
view, an NSP staff member transported each participant
to the local AIDS Center where a staff member trained
in HIV testing and counseling performed rapid HIV
antibody testing. If a participant tested positive for HIV
antibodies, an AIDS Center staff member collected
blood by finger stick onto filter paper as dried blood
spots and stored them in freezers at − 20 °C. The dried
blood spots were transported from Tajikistan to the Uni-
versity of North Carolina at Chapel Hill Virology La-
boratory, which performed the HIV viral load testing.
Analysis
The initial analyses used contingency tables and t tests
to compare participants in the two cities. The NSP in
each city ran out of LDS detachable needles before most
participants completed their follow-up interview. There-
fore, our analyses focused on two alternative outcomes.
The first analyses used logistic regression analysis to
examine the factors associated with preferring HDS nee-
dles. The second analyses used negative binomial regres-
sion to examine the factors associated with the number
of injections in the past 30 days with an HDS needle.
Analyses of both outcomes were limited to Khudjand
because only one participant in Kulob preferred HDS
needles, and all but one person in Kulob reported the
reason for using an HDS needle was because they were
unable to obtain an LDS needle.
The study team initially identified potential independ-
ent variables for the model based on previous qualitative
work and an examination of injecting practices in the
two cities reported at baseline. Because both sites dis-
tributed all their LDS needles before they completed all
their follow-up interviews, we also considered additional
variables that were likely to affect access to LDS detach-
able needles, such as frequency of injection and the
number of days from the start of the study until a par-
ticipant completed his or her follow-up interview. For
the logistic regression model, variables that were signifi-
cant (p < 0.2) in bivariate analyses were entered into the
multivariable model using a forward stepwise variable
selection procedure with criteria for entry set at p < 0.20
and removal at p < 0.25. The multivariable negative
binomial regression model initially included all variables
that were significant at p < 0.20 in the bivariate analyses.
Variables with the highest p values were removed
Zule et al. Harm Reduction Journal  (2018) 15:44 Page 5 of 10
manually from the model one at a time until only vari-
ables with p values < 0.20 remained.
Ethical approval and informed consent
The study received ethical approval from the Committee
of Medical Ethics of Tajikistan and the RTI International
Office of Human Research Protection. All participants
provided oral informed consent and received a food
package valued at the equivalent of $5 USD for their
participation in their initial interview and $10 USD for
participation in their follow-up interview. A Data and




Data collection for the study began in August 2015 and
ended in November 2015. The sample included 200 par-
ticipants (100 per city) who were recruited over a
1-month period in each city. Among the sample, three
fourths were male, with a mean age of approximately
38 years. Study participants in Kulob and Khudjand dif-
fered in potentially important respects, as shown in
Table 1. Almost 100% (199/200) of participants com-
pleted a 2-month follow-up interview.
Feasibility and penetration
During the study, both NSP offered all clients their
choice of HDS needles or LDS needles until they ran out
of LDS needles. All LDS needles at each site were
distributed in less than 2 months after the NSP began
offering them. The NSP in Khudjand distributes ap-
proximately 25,000 needles/syringes per month, which
means that LDS needles represented about 50% of all
needles/syringes distributed during the study period at
this NSP. The NSP in Kulob distributes 52,000 needles/
syringes per month, which means that LDS needles rep-
resented about 25% of the needles/syringes distributed
during the study period at this site.
Acceptability
NSP staff members in each city reported that many of
their clients preferred the LDS needles. At the 2-month
follow-up interview, 100% of participants in the pilot test
reported trying an LDS detachable needle, and 96% re-
ported that they liked using the needles.
Attributes of LDS detachable needles and rate of
adoption
At follow-up, 100% of study participants reported seeing
the flyer that explained the relative advantages of using
LDS needles. The two most frequently mentioned ad-
vantages of LDS needles were less drug waste (73%) and
less blood retention (61%) after use. Most (96%) study
participants reported observing other PWID using an
LDS needle, and 96% reported telling their friends about
LDS needles. In Kulob, 95% of participants reported that
they liked LDS needles because the needles wasted less
of their drug, and 99% reported they liked that the
needles retained less blood and may reduce their risk
of HIV and HCV. In Khudjand, only 51% endorsed
liking LDS needles because they wasted less of their
drug and only 24% endorsed liking LDS needles be-
cause they retained less blood and may reduce their
risk of infections.
Uptake
From the beginning to end, the enrollment and
follow-up process took 104 days in Khudjand and 91 days
in Kulob; as noted earlier, both NSPs distributed all their
LDS detachable needles within the first 60 days. Only
one participant in Kulob reported using HDS needles
because he preferred them, and 98 participants in Kulob
reported using that they used an HDS needle at
follow-up because they could not get a LDS detachable
needle. We do not present models for Kulob because the
distribution of these responses resulted in numerically
unstable models for both outcomes.
Prefer HDS needles
In bivariate analyses in Khudjand, usually using 1-mL sy-
ringes was negatively associated with preferring HDS
needles (odds ratio [OR] 0.36; 95% confidence interval
[CI] 0.13, 1.01; p = 0.051). The number of injections of
dimedrol mixed with heroin (OR = 1.03; 95% CI = 1.00,
1.05; p = 0.045) and the total number of injections in the
past 30 days (OR = 1.04; 95% CI 1.04, 1.08; p = 0.015)
were both positively associated with preferring HDS
needles (see Table 2). In the multiple logistic regres-
sion model, usually using 1-mL syringes was nega-
tively associated with preferring HDS needles (OR =
0.30; 95% CI = 0.10, 0.92), and the total number of in-
jections in the past 30 days was positively associated
with preferring HDS needles (OR = 1.04; 95% CI =
1.01, 1.07; p = 0.014).
Number of injections with HDS needles
In bivariate analyses using negative binomial regression,
male gender (incidence rate ratio [IRR] = 2.05; 95% CI =
1.25, 3.37; p value = 0.005), preferring HDS needles (IRR =
1.95; 95% CI = 1.25, 3.02; p = 0.003), number of injections
of dimedrol mixed with heroin (IRR = 1.04; 95% CI = 1.02,
1.05; p < 0.001), and the total number of injections (IRR
= 1.06; 95% CI = 1.04, 1.08; p < 0.001) were all positively
associated with the number of injections using an HDS
needle (Table 3). Using an HDS needle because a partici-
pant was unable to get an LDS detachable needle was
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negatively associated with the number of injections with
an HDS needle (IRR = 0.55; 95% CI 0.36, 0.83; p = 0.004),
In the multivariable model, being unable to get an
LDS detachable needle (IRR = 0.60; 95% CI = 0.39, 0.91;
p = 0.016) was negatively associated with the number of
injections with an HDS needle (IRR = 1.06; 95% CI =
1.04, 1.08; p < 0.001).
Impact of LDS detachable needles on HIV viral burden
Dried blood spots from 48 of the 54 participants who
tested positive for HIV were tested successfully for HIV
viral load. Six samples were damaged during collection,
storage, or transport. HIV viral load ranged from un-
detectable (< 50 copies/mL) to 1,280,192 copies/mL. The
mean number of copies was 128,323 (SD 346,521) and
Table 1 Characteristics of the sample (n = 199), by city—Kulob and Khudjand
Kulob (n = 99) Khudjand (n = 100) p value
Background characteristics
Mean age (standard deviation [SD]) 35.9 (8.4) 39.3 (7.3)
Percentage male 96.0 77.0 < 0.001
Percentage high school education or greater 53.0 81.0 < 0.001
Percentage unemployed 96.0 51.0 < 0.001
Percentage married or living as married 32.3 55.0 0.001
Percentage ever in substance abuse treatment 75.5 45.0 < 0.001
Percentage ever incarcerated 1 year or more 27.3 41.0 0.041
Percentage ever had a sexually transmitted infection 9.1 16.0 0.199
Percentage tested positive for HIV 22.2 31.0 0.161
Percentage hazardous or harmful drinkinga 42.4 51.0 0.225
Percentage reported using heroin daily with or without dimedrol during the past 30 days 90 8 < 0.001
Drug use and injecting practices
Mean number of injections past 30 days (SD) 67.3 (23.6) 21.9 (17.1) < 0.001
Mean number of injections with a high dead space needle in past 30 days (SD) 48.2 (35.2) 11.2 (14) < 0.001
Mean number of times injected heroin by itself in the past 30 days (SD) 15.3 (24.1) 1.5 (6.2) < 0.001
Mean number of times injected heroin mixed with dimedrol in the past 30 days (SD) 52.0 (34.1) 20.3 (17.6) < 0.001
Percentage any direct or indirect needle or syringe sharing in the past year 9.1 6.0 0.409
Mean number of days between project start and completion of follow-up interviews (SD) 81.8 (9.5) 78.7 (8.9) 0.019
Percentage injected homemade opiates in past 30 days 0.0 14.0 < 0.001
Percentage injected methamphetamine or another stimulant in past 30 days 0.0 0.0 –
Percentage injected prescription opiate in past 30 days 0.0 1.0 1.000
Percentage injected other prescription drug 0.0 11.0 0.001
Percentage injected any other drug 0.0 0.0 –
Do you like using low dead space needles? 99.0 92.9 0.065
What do you like about using low dead space needles?
Percentage less wasted drugs 94.9 51.0 < 0.001
Percentage they are free 57.6 99.0 < 0.001
Percentage it is easy to split drugs accurately 86.9 18.0 < 0.001
Percentage they save me money on drugs 85.9 64.0 < 0.001
Percentage they are healthier for me to use because less infected blood stays in them 99.0 24.0 < 0.001
Percentage did not use any high dead space needles 21.2 31.0 0.117
Reasons for using high dead space needles in past 30 days at follow-up (n = 78) (n = 69) < 0.001
Percentage prefer high dead space needles 1.3 44.9 < 0.001
Percentage could not get a low dead space needle 98.7 40.6 < 0.001
Percentage low dead space needles wrong size 0.0 13.0 0.001
Percentage low dead space needles poor quality 0.0 1.4 0.469
aBased on Alcohol Use Disorders Identification Test (AUDIT) classification score of 8 or higher (https://www.drugabuse.gov/sites/default/files/files/AUDIT.pdf)
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median 1952 copies/mL. LDS needles attached to HDS
syringes—assuming 21 μL of dead space—would retain
approximately 0.029 μL of blood after injection and rins-
ing [13]. At the mean HIV viral load, 0.029 μL of blood
would contain approximately 4 copies of HIV; at the
median, it would contain less than 1 copy of HIV. At the
mean viral load, the 1 μL of blood retained in an HDS
needle attached to an HDS syringe after injection and
rinsing [21] would contain 128 copies of HIV; at the
median, it would contain about 2 copies of HIV. In con-
trast, the 0.001 μL of blood retained in an LDS insulin
syringe with a permanently attached needle after injec-
tion and rinsing [21] would contain less than 1 copy of
HIV at both the median and mean HIV viral loads.
Discussion
At follow-up, 100% of participants reported trying the
LDS detachable needles. This followed a simple
Table 2 Logistic regression model for participants in Khudjand who prefer high dead space needles to low dead space needles
Variables Bivariate Multivariable
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Gender (female = 0, male = 1) 1.36 (0.48, 3.88) 0.562
Age in years 0.99 (0.93, 1.05) 0.715
High school education or more 0.41 (0.15, 1.15) 0.092
Pharmacy main source of syringes at follow-up 1.87 (0.72, 4.86) 0.198 2.12 (0.74, 6.11) 0.162
Usually used 12-mm/ 0.5-in. needles 0.58 (0.17, 1.94) 0.378
Usually used 1-mL syringes 0.36 (0.13, 1.01) 0.051 0.30 (0.10, 0.92) 0.035
Injected homemade opiates at follow-up 0.56 (0.15, 2.19) 0.408
Like LDS needles because they waste less drugs 1.04 (0.44, 2.42) 0.935
Like LDS needles because they make it easier to split drugs accurately 0.58 (0.17, 1.94) 0.378
Like LDS needles because they save money on drugs 0.69 (0.29, 1.65) 0.408
Like LDS needle because they are healthier to use because less infected blood
stays in them
0.89 (0.33, 2.44) 0.824
Number of injections with heroin mixed with dimedrol in the past 30 days 1.03 (1, 1.05) 0.045
Number of injections with heroin by itself in the past 30 days 1.07 (0.98, 1.17) 0.142
Total number of injections past 30 days 1.04 (1.01, 1.08) 0.015 1.04 (1.01, 1.07) 0.014
Table 3 Negative binomial regression for frequency of using HDS needles in Khudjand
IRR (95% CI) p value IRR (95% CI) p value
Gender (female = 0, male = 1) 2.05 (1.25, 3.37) 0.005
Age in years 0.98 (0.95, 1.01) 0.202
Completed high school or more (no = 0, yes = 1) 0.72 (0.43, 1.21) 0.217
Prefers regular needles to LDS needles = 1.00 1.95 (1.25, 3.02) 0.003
Pharmacy main source of syringes 1.48 (0.92, 2.38) 0.106
Unable to get LDS 0.55 (0.36, 0.83) 0.004 0.60 (0.39, 0.91) 0.016
Injected homemade opiates 1.48 (0.83, 2.66) 0.187 1.54 (0.85, 2.79) 0.158
Like LDS because they waste less drugs 0.94 (0.63, 1.42) 0.775
Like LDS because needles because they are free 1.87 (0.22, 15.69) 0.564
Like LDS needles because they make it easier to split drugs accurately 0.70 (0.41, 1.19) 0.187
Like LDS needles because less infected blood stays in them 0.81 (0.50, 1.31) 0.397
Usually used 12-mm/ 0.5-in. needles 0.91 (0.53, 1.55) 0.730
Usually used 1-mL syringes 1.02 (0.66, 1.58) 0.932
Number of times injected heroin mixed with dimedrol in the last 30 days? 1.04 (1.02, 1.05) < 0.001
Number of times injected heroin by itself in the last 30 days? 1.02 (0.99, 1.05) 0.166
Number of injections in the last 30 days? 1.06 (1.04, 1.08) < 0.001 1.06 (1.04, 1.08) < 0.001
Number of days between the start of the study and follow-up interview completed 1.00 (0.98, 1.02) 0.931
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intervention (i.e., distributing LDS detachable needles
and a flyer that explained their benefits). Both NSPs
in the study distributed the flyer and needles without
difficulty. According to NSP records, both NSPs dis-
tributed all (25,000 per NSP) of their LDS detachable
needles in less than 2 months. This suggests that the
LDS detachable needles achieved high penetration
among NSP clients beyond the study sample. Al-
though other reports have examined the acceptability
of LDS detachable needles and syringes among NSP
clients [16, 22], this is one of the first studies to
demonstrate the feasibility of NSPs influencing their
clients to use LDS detachable needles.
The flyer seemed to be particularly effective at market-
ing the LDS needles to participants in Kulob where 95%
endorsed liking LDS needles because they waste less of
their drug, 87% endorsed liking them because they made
it easier to split drugs accurately, and 99% endorsed
liking them because they retained less blood and
may reduce their risk of HIV and HCV. Moreover,
almost all use of HDS needles at follow-up seemed
to be because participants were unable to obtain
LDS detachable needles. In contrast, the flyers
seemed to be much less effective at marketing LDS
detachable needles in Khudjand. Only 51% of partici-
pants endorsed liking LDS because they wasted less
drug, 18% endorsed liking them because they made
it easier to split drugs accurately, and 24% endorsed
liking them because they retained less blood and
may reduce risk of HIV and HCV. Nevertheless,
even in Khudjand, 31% reported that they did not
use any HDS needles in the past 30 days at
follow-up, and only 45% (n = 31) of those who did
use an HDS needle reported that they preferred
HDS needles. Moreover, preferring HDS needles was
not significant in the multivariable model for the
number of injections using an HDS needle.
Potential impact of switching to LDS detachable needles
Studies point to a lower risk of HIV and HCV transmis-
sion associated with LDS needles attached to HDS syrin-
ges compared with HDS needle and syringe combinations
[14, 15]. These studies tested the first-generation LDS de-
tachable needles. When first-generation 25 g LDS detach-
able needles were attached to a 2-mL HDS syringe, the
dead space was 54 μL, whereas the dead space in the
current (third-generation) generation of 25 g LDS detach-
able needles attached to a 2-mL HDS syringe is 17 μL (A.
Preston, Exchange Supplies, personal communication, No-
vember 17, 2016). Consequently, it is likely that the reduc-
tion in risk associated with the current generation of LDS
detachable needles is greater than the reduction observed
in those studies [13].
Limitations
This study did not include a comparison arm, which
weakens our ability to attribute changes to the project
[23]. However, prior to the study, LDS detachable nee-
dles were not available in either of the study cities. Dur-
ing the study, there were no other potential sources of
LDS detachable needles, and no other organizations
were encouraging PWID to use LDS detachable needles.
Therefore, attributing the use of LDS detachable needles
to the intervention is reasonable.
Both NSP ran out of LDS detachable needles while the
data collection was in progress, which made it impos-
sible for the participants to continue using the needles.
Therefore, we cannot be certain how many participants
would have continued using the needles if they had been
available. However, at follow-up, 71% of people who re-
ported any injections in the past 30 days with other
types of needles reported that they did so because they
were unable to obtain an LDS detachable needle. An-
other limitation is that this study did not test strategies
for NSP to switch their clients from HDS needles to
LDS insulin syringes with permanently attached needles,
which retain substantially less blood after use than the
LDS detachable needles retain. Natural experiments have
shown that under certain conditions, people who inject
drugs will switch from HDS detachable needles to LDS
insulin syringes with permanently attached needles [24].
However, it is not clear if similar changes would occur
in settings where people inject volumes of fluid greater
than 1 mL and the largest LDS insulin syringes with per-
manently attached needles are 1 mL.
Conclusions
The pilot study findings have important implications for
NSPs that are considering offering LDS equipment. In
areas where most PWID will not use LDS insulin syrin-
ges, NSPs should offer LDS detachable needles in
addition to LDS insulin syringes. More generally, the
study findings highlight the importance of balancing the
selection of interventions for implementation based on a
combination of efficacy and acceptability. Highly effica-
cious interventions that are not compatible with the
values and beliefs of both the intended recipients and
the service providers who will be delivering them may
have limited impact. While striving to implement perfect
solutions to problems, policymakers, harm reductionists,
and public health workers must not let the quest for per-
fection prevent or delay implementation of viable and
feasible solutions, such as distributing LDS detachable
needles.
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